Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 2,685 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,685 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $71,904.30. Following the completion of the sale, the insider owned 147,499 shares of the company’s stock, valued at $3,950,023.22. This trade represents a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ:KALV traded up $0.02 during trading on Tuesday, hitting $26.81. The company’s stock had a trading volume of 8,068,030 shares, compared to its average volume of 7,414,539. The business has a 50 day moving average price of $21.74 and a two-hundred day moving average price of $17.54. The company has a market capitalization of $1.43 billion, a PE ratio of -7.75 and a beta of -0.12. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $26.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $39.17 million for the quarter, compared to analyst estimates of $39.03 million. As a group, research analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC raised its holdings in shares of KalVista Pharmaceuticals by 45.8% in the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 589 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 818 shares during the period. BNP Paribas Financial Markets increased its stake in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Rhumbline Advisers increased its stake in shares of KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after acquiring an additional 1,458 shares during the period. Finally, Royal Bank of Canada increased its stake in shares of KalVista Pharmaceuticals by 137.0% during the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 1,686 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. HC Wainwright cut shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $37.00 to $27.00 in a research report on Friday, May 1st. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.